References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2019-6-27-33

medsovet-2972

Research Article

НЕВРОЛОГИЯ

NEUROLOGY

Практические алгоритмы ведения пациентов с когнитивными нарушениями

Practical algorithms for managing patients with cognitive impairments

Захаров

В. В.

Zakharov

V. V.

Захаров Владимир Владимирович – доктор медицинских наук, профессор кафедры нервных болезней и нейрохирургии

119991, г. Москва, ул. Трубецкая, 8, стр. 2

Zakharov Vladimir Vladimirovich – Dr. of Sci.(Med.), Professor, Chair for Nervous Diseases and Neurosurgery

8, Trubetskaya Street, Moscow, 119991, p. 2

Вахнина

Н. В.

Vakhnina

N. V.

Вахнина Наталья Васильевна – кандидат медицинских наук, доцент кафедры нервных болезней и нейрохирургии

119991, г. Москва, ул. Трубецкая, 8, стр. 2

Vakhnina Natalya Vasilyevna – Cand. of Sci. (Med.), Associate Professor, Chair for Nervous Diseases and Neurosurgery

8, Trubetskaya Street, Moscow, 119991, p. 2

Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияFederal State Autonomous Educational Institution of Higher Education Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation

2019

25042019

062733

2019

Захаров В.В., Вахнина Н.В.

Zakharov V.V., Vakhnina N.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/2972

В статье изложены современные подходы к ведению пациентов с когнитивными нарушениями различной этиологии. Приведены алгоритмы синдромальной (легкие, умеренные, выраженные) и нозологической дифференциальной диагностики когнитивных расстройств, показано место диагностических лабораторных, инструментальных и нейрорадиологических методов исследования. Обсуждаются данные последних исследований об эффективности когнитивного тренинга, оптимизации образа жизни, физической активности, профилактическом значении своевременного лечения сердечно-сосудистых и иных заболеваний. Показаны возможности современной нейропротективной и симптоматической терапии когнитивных нарушений различной этиологии, место EGB 761 в лечении заболеваний с когнитивными нарушениями.

The article presents modern approaches to the management of patients with cognitive impairment of different etiology. The authors presented the algorithms for syndromic (mild, moderate, severe) and nosological differential diagnosis of cognitive disorders, and showed the importance of diagnostic laboratory, instrumental and neuroradiological research methods. They discussed the latest research data on the effectiveness of cognitive training, lifestyle optimization, physical activity, and the prophylactic value of timely treatment of cardiovascular and other diseases. The paper shows the possibilities of modern neuroprotective and symptomatic therapy of cognitive impairment of different etiology, the role of EGB 761 in the treatment of diseases with cognitive impairment.

когнитивные нарушениядеменциянейропротективная терапияэкстракт гинкго билоба

cognitive impairmentdementianeuroprotective therapyginkgo biloba extract

References1

Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал. 2006;11:27-32.

Zakharov V.V. All-Russian program of study of cognitive disorders epidemiology and therapy in the elderly. («Prometheus») Nevrologichesky Zhurnal. 2006;11:27-32 (In Russ).

Kivipelto M., Ngandu T., Laatikainen T. et al. Risk score for the prediction of the dementia risk for 20 years among middle-aged people: a longitudinal, population-based study. Lancet Neurology. 2006;5(9):735-741.

Folstein M.F., Folstein S.E., McHugh P.R. MiniMental State: a practical guide for grading the mental state of patients for the clinician. J Psych Res. 1975;12:189-198.

Nasreddine Z.S., Philips N.A., Bedirian V. et al. The Montreal cognitive assessment, MoCa: a brief screening tool for mild cognitive impairment. J Am Ger Soc. 2005;53(4):695-699.

Яхно Н.Н., Преображенская И.С., Захаров В.В., Степкина Д.А., Локшина А.В., Мхитарян Э.А., Коберская Н.Н., Савушкина И.Ю. Распространенность когпитивных нарушений при неврологических заболеваниях (анализ работы специализированного амбулаторного приема). Неврология, нейропсихиатрия, психосоматика. 2012;2:30-34.

Yakhno N.N., Preobrazhenskaya I.S., Zakharov V.V., Stepkina D.A., Lokshina A.V., Mkhitaryan E.A., Koberskaya N.N., Savushkina I. Yu. Prevalence of cognitive impairment in neurological diseases (analysis of the specialized outpatient visit). Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2012; 2: 30-34. (In Russ)

Вейн А.М., Вознесенская Т.Г., Голубев В.Л., Дюкова Г.М. Депрессия в неврологической практике, 3-е изд. М.: МИА. 2007. 208 с.

Wayne AM, Voznesenskaya T.G., Golubev V.L., Dyukova G.M. Depression in Neurological Practice, 3rd Edition. Moscow, MIA. 2007. 208 p. (In Russ).

Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б., Дробижев М.Ю., Шальнова С.А., Погосова Г.В. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;9:1–8.

Oganov R.G., Olbinskaya L.I., Smulevich A. B., Drobizhev M.Yu., Shalnova S.A., Pogosova G.V. Depression and depressive disorders in general medical practice. Results of the COMPASS program. Kardiologiya. 2004;9:1–8. (In Russ).

The ESEMed/MHEDEA 2000 Investigators. Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109(Suppl. 420):21–27.

Conradi H.J., Ormel J., de J.P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol. Med. 2011;41(6):1165-1174.

Sapolsky R.N. Depression, antidepressants and the shrinking of the hippocampus. Natl Acad Sci. 2001;98(22):12320-12322.

Вознесенская Т.Г. Акатинол в лечении некогнитивных нервно-психических расстройств при нейрогериатрических заболеваниях. Nevrologiya, Neyropsikhiatriya, Psikhosomatika. 2012;4(2S):11- 17.

Voznesenskaya T.G. Akatinol in the treatment of non-cognitive neuropsychiatric disorders in neuro-geriatric diseases. Neurology, neuropsychiatry, psychosomatics. 2012;4(2S):11-17. (In Russ).

Ankolekar S., Geeganage C., Anderton et al. Clinical trials for prevention post stroke cognitive impairment. J of Neurological Sciences. 2010;299:168-174.

Haag M.D., Hofman A., Koudstaal P.J. et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72:1727-1234.

Perila R., White L.R., Masaki K. et al. Reducing the risk of dementia: efficacy of long term treatment of hypertension. Stroke. 2006;37:1165-1170.

Guo Z., Fratiglioni L., Zhu L. et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56:991-996.

Khachaturian A.S., Zandi P.P., Lyketos C.G. et al. Antihypertensive medication use and incidence of Alzheimer’s disease: the Cache County Study. Arch Neurol. 2006;63:686-692.

Qui C., von Strauss E., Fastbom J. et al. Low blood pressure and risk of dementia in the Kungholmen study: a 6 years follow-up study. Arch Neurol. 2003;60:223-228.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22.

Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L.E.M., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

McGuinness B., Craig D., Bullock R., Passmore P. Statins for the treatment of dementia. Cohrane Database Syst Rev. 2014;8(7):CD 007514.

Price J.F., Stewart M.C., Deary I.J. et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomized controlled trial. BMJ. 2008;437:1198.

Diener H.C., Sacco R.L., Yusuf S. et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo controlled study. Lancet Neurol. 2008;7:875–884.

Guire C.B., Ibrahim N.A., Adam M.B., Said S.M. Impact of physical activity on cognitive decline, dementia and its subtypes: meta-analysis of prospective studies. Biomed Res Int. 2017;2017:9016924.

Sofi F., Valecchi D., Bacci D., et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. Journal of Internal Medicine. 2011;269(1):107–117.

Hamer M., Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychological Medicine. 2009;39(1):3–11.

Blondell S.J., Hammersley-Mather R., Veerman J.L. Does physical activity prevent cognitive decline and dementia?: a systematic review and meta-analysis of longitudinal studies. BMC Public Health. 2014;14:510.

Wang H.-X., Karp A., Winblad B., Fratiglioni L. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. American Journal of Epidemiology. 2002;155(12):1081–1087.

Kishimoto H., Ohara T., Hata J., et al. The longterm association between physical activity and risk of dementia in the community: the Hisayama Study. European Journal of Epidemiology. 2016;31(3):267–274.

Laurin D., Verreault R., Lindsay J., MacPherson K., Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Archives of Neurology. 2001;58(3):498–504.

Morgan G. S., Gallacher J., Bayer A., Fish M., Ebrahim S., Ben-Shlomo Y. Physical activity in middle-age and dementia in later life: findings from a prospective cohort of men in caerphilly, South Wales and a meta-analysis. Journal of Alzheimer’s Disease. 2012;31(3):569–580.

Butler M., McCreedy E., Nelson V.A., Desai P., Ratner E., Fink H.A., et al. Does Cognitive Training Prevent Cognitive Decline? A Systematic Review. Ann Intern Med. 2018;168:63–68.

Smart C.M., Karr J.E., Areshenkoff C.N. et al. NonPharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychol Rev. 2017;27:245-257.

Smith P.J., Blumenthal J.A. Dietary factors and cognitive decline. J Prev Alzheimers Dis. 2016;3(1):53-64.

Martinez-Lapiscina E.H., Clavero P., Toledo E., Estruch R., Salas-Salvado J., San Julian B., Sanchez-Tainta A., Ros E., Valls-Pedret C., Martinez-Gonzalez M.A. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-25.

Estruch R., Ros E., Salas-Salvadó J., Covas M.I., Corella D., Arós F., Gómez-Gracia E., RuizGutiérrez V., Fiol M., Lapetra J., LamuelaRaventos R.M., Serra-Majem L., Pintó X., Basora J., Muñoz M.A., Sorlí J.V., Martínez J.A., MartínezGonzález M.A., PREDIMED Study Investigators. N Engl J Med. 2013;368(14):1279-1290.

Ngandu T., Lehtisalo J., Solomon A. et al. A 2 year multidomain intervention of diet, exercise, cognitive training and vascular risk monitoring versus control to prevent cognitive decline in atrisk elderly people (FINGER): a randomized control trial. Lancet. 2015;385(9984):2255-2263.

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Libr. 2009. doi: 10.1002/14651858.CD001191.

Chen Y., Zhang J., Wang Y., Yuan J., Hu W. Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis. Eur Neurol. 2016;75:132–141.

McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews. 2006;2:CD003154.

Thomas S.J., Grossberg G.T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias. Clinical intervention in aging. 2009;4:367-377.

Napryeyenko O., Borzenko I.; GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4-11.

Ihl R. Gingko biloba extract EGb 761®: clinical data in dementia. Int Psychogeriatr. 2012;24:35-40.

Ihl R., Bachinskaya N., Korczyn A.D., Vakhapova V., Tribanek M., Hoerr R., Napryeyenko O.; GOTADAY Study Group. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26(11):1186-94.

Mazza M., Capuano A., Bria P., Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double blind study. Eur J Neurol. 2006;13(9):981-5.

Koltringer P., Langsteger W., Ober O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. Clinical Hemorheology. 1995;15:649–656.

Rosler M., Retz W., Thome J., Riederer P. Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl. 1998;54:211–219.

Abdel-Kader R., Hauptmann S., Keil U., Scherping I., Leuner K., et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research. 2007;56:493–502.

Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., et al. Amyloid-binduced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761and ginkgolides in transgenic Caenorhabditis elegans. Journal of Neuroscience. 2006;26:13102–13113.

Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A. 2002;99(19):12197–12202.

Яхно Н.Н., Захаров В.В., Локшина А.Б., Гаврилова С.И., Федорова Я.Б., Густов А.В., Коршунова Ю.А., Дзяк Л.А., Мизякина Е.В., Одинак М.М., Емелин А.Ю., Пилипенко П.И., Вострикова Е.В. Танакан (EGb 761) в терапии умеренных когнитивных нарушений (мультицентровое исследование). Журн. неврологии и психиатрии. 2006;12:41–6.

Yakhno N.N., Zakharov V.V., Lokshina AB, Gavrilova S.I., Fedorova Ya.B., Gustov A.V., Korshunova Yu.A., Dzyak L.A., Mizyakina E.V., Odinak M.M., Emelin A.Yu., Pilipenko P.I., Vostrikova E.V. Tanakan (EGb 761) in the treatment of moderate cognitive impairment (multicenter study). Zhurn.Nevrologii i Psikhiatrii. 2006;12:41–6. (In Russ).

Шахпаронова Н.В., Кадыков А.С. Место препарата Билобил в комплексной терапии сосудистых заболеваний головного мозга. Лiки Украiни. 2010;9:54–6.

Shakhparonov N.V., Kadykov A.S. Place of Bilobil in the complex therapy of vascular brain diseases. Liki Ukrainy. 2010;9:54–6. (In Russ).

Яхно Н.Н., Суслина З.А., Грибачева И.А., Одинак М.М., Коберская Н.Н., Мхитарян Э.А. Влияние препарата Билобил форте на умеренные когнитивные нарушения у пациентов с дисциркуляторной энцефалопатией 1–2 стадии. Клиниконейропсихологическое исследование. РМЖ. 2007;16(12):1626-1629.

Yakhno N.N., Suslina Z.A., Gribacheva I.A., Odinak M.M., Koberskaya N.N., Mkhitaryan E.A. Effect of Bilobil Forte on moderate cognitive impairment in patients with stage 1-2 dyscirculatory encephalopathy. Clinical and neuropsychological research. RMJ. 2007;16(12):1626-1629. (In Russ).

Тимербаева С.Л., Суслина З.А., Бодарева Э.А., Федин П.А., Корепина О.С., Первозванский Б.Е. Танакан в лечении начальных проявлений недостаточности кровоснабжения мозга: эффективность, переносимость и отдаленные результаты. Журн. неврол. и психиатр.им. С.С. Корсакова. 1999:54-61.

Timerbaeva S.L., Suslina Z.A., Bodareva E.A., Fedin P.A., Korepina OS, Pervozvansky B.E. Tanakan in the treatment of the initial manifestations of cerebral circulation insufficiency: efficacy, tolerability and long-term results. Zhurn. Nevrol. i psykhiatr. im. S.S. Korsakov. 1999:54-61. (In Russ).

Яхно Н.Н., Дамулин И.В., Захаров В.В., Елкин М.Н., Ерохина Л.Г., Стаховская Л.В., Чекнева Н.С., Суслина З.А., Тимербаева С.Л., Федин П.А., Бодарева Э.А., Скоромец А.А., Сорокоумов В.А., Ивашкин В.Т., Гигорьев Ю.В., Первозванский Б.Е. Применение танакана при начальных стадиях сосудистой мозговой недостаточности: результаты открытого мультицентрового исследования. Неврол. журн. 1998;3:18-22.

Yakhno N.N., Damulin I.V., Zakharov V.V., Elkin M.N., Erokhina L.G., Stakhovskaya L.V., Chekneva N.S., Suslina Z.A., Timerbaeva S.L., Fedin P.A., Bodareva E.A., Skoromets A.A., Sorokoumov V.A., Ivashkin V.T., Gigoryev Yu.V., Pervozvansky B.E. Use of tanakan in the treatment of primary manifestations of cerebral vascular insufficiency: results of an open multicenter study. Nevrol. Zhurn. 1998;3:18-22. (In Russ).

Morgenstern C., Biermann E. The efficacy of Ginkgo biloba Special Extract EG 761 in patients with tinnitus. International J Clin Farmacol Ther. 2002;40:188–97.

Andrieu S., Gillette S., Amouyal K., Nourhashemi F., Reynish E., Ousset P.J., Albarede J.L., Vellas B., Grandjean H.; EPIDOS study. Association of Alzheimer’s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci. 2003;58(4):372-7.

Amieva H., Meillon C., Helmer C. et al. Gingko biloba extract and long term cognitive decline: a 20 years follow up population based study. PLoS One. 2013;8(1):e52755.

Зайцева О.В. Роль танакана в повышении эффективности вестибулярной реабилитации. Вестник отоларингологии. 2014;5:66-68.

Zaitseva O.V. The role of tanakan in enhancing the effectiveness of vestibular rehabilitation. Vestnik Otolaringologii. 2014;5:66-68. (In Russ).

Кунельская НЛ., Левина Ю.В., Красюк А.А., Доронина О.М. Оценка эффективности и переносимости танакана при лечении нейросенсорной тугоухости и ушного шума. Вестник отоларингологии. 2009;2:40-42.

Kunelskaya N.L., Levina Yu.V., Krasyuk A.A., Doronina O.M. Evaluation of the efficacy and tolerability of tanakan in the treatment of sensorineural hearing loss and ear noise. Vestnik Otolaringologii. 2009;2:40-42. (In Russ).

Vellas B., Coley N., Ousset P.J., Berrut G., Dartigues J.F., et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851–859.

The authors declare that there are no conflicts of interest present.